Novartis, lagging some other big drugmakers in the first wave of immunotherapy drugs that are revolutionizing cancer treatment, is focusing on the next wave of immune system-boosting medicines.
Corbus Pharmaceuticals Holdings Inc. said its only drug outperformed a placebo in a mid-stage study involving patients with a form of systemic sclerosis.
Shire Plc said the U.S. FDA approved its treatment for patients with primary immunodeficiency, a group of genetic disorders.
Rigel Pharmaceuticals Inc. said its experimental drug to treat a bleeding disorder met its main goal in the first of two late-stage trials.
Recent clinical trial results are likely to lead doctors to treat more patients who have a common form of lung cancer with a Merck drug at the expense of a Bristol-Myers Squibb medication at least until more data emerges, oncologists and analysts say.
Evelo BioSciences and Epiva Biosciences will combine efforts to become a leading immuno-microbiome platform company in the U.S.
The outlook remains bright due to a favorable regulatory arena, support for biopharma-friendly legislation and development incentives, expanding scientific opportunities in key therapeutic areas such as immuno-oncology, and big pharma’s continued push to obtain innovation.
Here are five company stocks that some industry analysts say are under the radar and/or could be a great bargain in 2016 per BioSpace.com sources …
The world’s first life-saving gene therapy for children, developed by GlaxoSmithKline and Italian scientists, was approved for sale in Europe.
Cambridge, Massachusetts-based Agios Pharmaceuticals inked a new global collaboration deal with Summit, New Jersey-based Celgene.